TCF7L2 and pancreatic neoplasm: Importantly, ChIP assay demonstrated a significant increase in the binding of TCF7L2 protein to the Gαi3 promoter region, as predicted in the JASPAR database, across various pancreatic cancer cells (Fig. 8G).